1 / 10

Neuroendocrine Tumors

Neuroendocrine Tumors. James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson Cancer Center. Neuroendocrine Tumors. Spectrum of neoplasms. WHO classification Well differentiated neuroendocrine tumor

savagel
Download Presentation

Neuroendocrine Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neuroendocrine Tumors James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson Cancer Center

  2. Neuroendocrine Tumors • Spectrum of neoplasms. • WHO classification • Well differentiated neuroendocrine tumor • Well differentiated neuroendocrine carcinoma • Poorly differentiated neuroendocrine carcinoma • Generally more indolent then adenocarcinoma of the same site. • Capable of producing hormonal syndrome (ie carcinoid syndrome).

  3. Epidemiology SEER

  4. All malignant neoplasm Malignant NETs Yao, unpublished data

  5. ~ ~ ~ ~ 2004 Prevalence estimate29-year limited duration prevalence analyses Yao, unpublished data

  6. Distant Localized Regional 1.00 1.00 1.00 0.90 0.90 0.90 0.80 0.80 0.80 0.70 0.70 0.70 0.60 0.60 0.60 0.50 0.50 0.50 Survival Probability Survival Probability Survival Probability 0.40 0.40 0.40 0.30 0.30 0.30 0.20 0.20 0.20 0.10 0.10 0.10 0.00 0.00 0.00 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10 Years Years Years Neuroendocrine versus non-neuroendocrine histologies NET Non-NET

  7. Localized Regional Survival probability Months Distant Median survival in months Survival probability Months Significant differences among neuroendocrine tumors of various sites

  8. Neuroendocrine Tumors: Current Situation (1) • Diagnosed incidence is on the rise. • Vastly different outcome compare to more common neoplasm of the same anatomic site. • Vastly different treatment offered. • Adenocarcinoma: Cytotoxic chemotherapy +/- newer targeted agents • Neuroendocrine: Hormonal therapy, interferon, newer targeted agents

  9. Neuroendocrine Tumors: Current Situation (2) • No ICD-9-CM diagnosis codes except: • 157.4 Malignant neoplasm, Islets of Langerhans (pancreatic subset of neuroendocrine tumors). • 259.2 Carcinoid syndrome (only small subset of neuroendocrine patients has carcinoid syndrome). • This leads to… • Lack of precision in coding. • Misleading statistics. • No way to accurately bill for services.

More Related